OverviewSuggest Edit

Incyte is a biopharmaceutical company focused on the discovery, development, and commercialization of proprietary therapeutics. The Company develops Jakafi (ruxolitinib), a drug for the treatment of intermediate or high-risk myelofibrosis, a type of myeloproliferative disorder that affects the bone marrow, and for polycythemia vera when there has been an inadequate response to or intolerance of hydroxyurea.

HQWilmington, DE, US
Employee Ratings3.6
Overall CultureA+

Latest Updates

Employees (est.) (Dec 2019)1,456(+7%)
Job Openings138
Revenue (FY, 2020)$2.7 B(+24%)
Share Price (Sept 2021)$73.4(+2%)
Cybersecurity ratingBMore

Key People/Management at Incyte

Hervé Hoppenot

Hervé Hoppenot

Chairman, President and Chief Executive Officer
Michael Booth D.phil

Michael Booth D.phil

Division VP, Investor Relations & Corporate Responsibility Phone: 302.498.5914
Jonathan E Dickinson

Jonathan E Dickinson

Executive Vice President, General Manager, Europe
Lauren Ayala

Lauren Ayala

Senior Director, Investor Relations & Corporate Responsibility
Christine Chiou

Christine Chiou

Senior Director, Investor Relations
Barry P. Flannelly

Barry P. Flannelly

Executive Vice President and General Manager, North America
Show more

Incyte Office Locations

Incyte has offices in Wilmington, Wien, Pointe-Claire, Frederiksberg and in 8 other locations
Wilmington, DE, US (HQ)
1801 Augustine Cut Off
Wien, AT
DC Tower 1 7 Donau-City-Straße
Pointe-Claire, CA
6500 Trans-Canada Hwy # 400
Frederiksberg, DK
Suomisvej 4
Boulogne-Billancourt, FR
35 Avenue André Morizet
Planegg, DE
9 Fraunhoferstraße
Show all (12)

Incyte Financials and Metrics

Incyte Revenue

Incyte's revenue was reported to be $2.67 b in FY, 2020

Revenue (Q1, 2021)


Gross profit (Q1, 2021)


Gross profit margin (Q1, 2021), %


Net income (Q1, 2021)


EBIT (Q1, 2021)


Market capitalization (15-Sept-2021)


Closing stock price (15-Sept-2021)


Cash (31-Mar-2021)



Incyte's current market capitalization is $16.2 b.
USDQ1, 2011

Financial Leverage

-4.4 x
Show all financial metrics

Incyte Cybersecurity Score

Cybersecurity ratingPremium dataset



SecurityScorecard logo

Incyte Online and Social Media Presence

Embed Graph

Incyte Company Culture

  • Overall Culture



  • CEO Rating



  • Compensation



Learn more on Comparably

Incyte News and Updates

Should You Buy Incyte Stock Around $75 Levels?

We believe that the stock price of Incyte, a global biopharmaceutical company, is undervalued at current levels of $75. INCY stock is down 21% over the last-twelve months period, despite revenue increasing 17% over the same period. Looking at a longer time period, INCY stock is also down 20% from...

Lilly and Incyte provide update on supplemental New Drug Application for baricitinib for the treatment of moderate to severe atopic dermatitis

INDIANAPOLIS, July 16, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ:INCY) announced today that the U.S. Food and Drug Administration (FDA) will not meet the Prescription Drug User Fee Act (PDUFA) action date for the supplemental new drug application (sNDA) for...

Global Myelodysplastic Syndrome Treatment Drugs Market (2021 to 2029) - Featuring Bayer, Celgene and Incyte Among Others

Dublin, June 17, 2021 (GLOBE NEWSWIRE) -- The "Myelodysplastic Syndrome (MDS) Treatment Drugs Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2021 to 2029" report has been added to ResearchAndMarkets.com's offerin…

Anti-CD19 Antibody Pipeline Report, 2021 Featuring TG Therapeutics, Merck kGaA, Generium Pharmaceutical, Sanofi, Incyte Corporation, Amgen, Viela Bio, and others

Approximately 15+ key companies are developing Anti-CD19 Antibody. The companies with their Anti-CD19 Antibody-drug candidates in the most advanced stage include Viela Bio, ADC Therapeutics, Amgen, Morphosys and Xencor. Approximately 15+ key companies are developing Anti-CD19 Antibody. The companies…

Eli Lilly and Incyte say Phase 3 study of baricitinib in hospitalized COVID-19 patients failed to meet main goal

Eli Lilly & Co. and Incyte Corp. said Thursday a Phase 3 trial of rheumatoid arthritis treatment baricitinib plus standard of care (SoC) versus placebo plus SoC failed to meet its main goal. The trial's primary endpoint was defined as a difference in the number of patients needing non-invasive…

Lilly and Incyte announce results from the Phase 3 COV-BARRIER study of baricitinib in hospitalized COVID-19 patients

INDIANAPOLIS, April 8, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ:INCY) announced today results of COV-BARRIER, a Phase 3 study evaluating baricitinib 4 mg once daily plus standard of care (SoC) versus placebo plus SoC. The trial did not meet statistical...
Show more

Incyte Frequently Asked Questions

  • When was Incyte founded?

    Incyte was founded in 1991.

  • Who are Incyte key executives?

    Incyte's key executives are Hervé Hoppenot, Michael Booth D.phil and Jonathan E Dickinson.

  • How many employees does Incyte have?

    Incyte has 1,456 employees.

  • What is Incyte revenue?

    Latest Incyte annual revenue is $2.7 b.

  • What is Incyte revenue per employee?

    Latest Incyte revenue per employee is $1.8 m.

  • Who are Incyte competitors?

    Competitors of Incyte include Alembic Pharmaceuticals, UCB and EMS Pharma.

  • Where is Incyte headquarters?

    Incyte headquarters is located at 1801 Augustine Cut Off, Wilmington.

  • Where are Incyte offices?

    Incyte has offices in Wilmington, Wien, Pointe-Claire, Frederiksberg and in 8 other locations.

  • How many offices does Incyte have?

    Incyte has 12 offices.